Assurant (AIZ) Q2 2025 10-Q Quarterly Report
Assurant (AIZ) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 7, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Assurant Q2 2025 10-Q Analysis
Management Discussion & Analysis
- • No quarterly revenue or YoY change figures provided
- • No profitability or margin percentage data included
- • Mobile business exposed to volatility in trade-in volumes and margins from device release timing and carrier promotions
- • Homeowners revenue influenced by housing market and voluntary insurance trends
- • Management highlights competitive pressures, labor shortages, wage inflation as emerging headwinds impacting growth and talent retention
Risk Factors
- • New $500M five-year senior unsecured revolving Credit Facility effective June 2025, replacing prior facility, with $750M increase option through 2030
- • Debt maturities of $175M due February 2026, $300M due March 2028, and $350M due February 2030 remain near-term liquidity focus
- • Letters of credit outstanding at $1.7M as of June 30, 2025, primarily supporting reinsurance, with required indemnifications to issuing banks
- • Operating cash flow down to $657.9M for Six Months 2025 from $793.4M in 2024 due to higher claims and timing of premiums and tax payments
- • Increased investing cash outflows of $784.5M in Six Months 2025 driven by reinvestment of proceeds and higher net cash investment versus $521.6M prior year
Assurant Q2 2025 Quarterly FinancialsXBRL
Revenue
$3.2B
▲ +8.0% YoY▲ +2.7% QoQ
Net Income
$235M
▲ +24.7% YoY▲ +60.5% QoQ
Net Margin
7.4%
▲ +100bp YoY▲ +268bp QoQ
Source: XBRL data from Assurant Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Assurant Quarterly Reports
Get deeper insights on Assurant
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.